Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in inflammatory bowel disease irrespective of azathioprine cotreatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Letter to the Editor

    Publikation: Bidrag til tidsskriftKommentar/debatForskning

  2. Symptoms and biomarkers associated with celiac disease: evaluation of a population-based screening program in adults

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bacterial infections in alcoholic and nonalcoholic liver cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Is the SPINK1 variant p.N34S overrepresented in patients with acute pancreatitis?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Quality of life assessment among patients with peristomal skin disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Antibiotic treatment during early childhood and risk of type 1 diabetes in children: A national birth cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Inflammatory Bowel Disease Increases Risk of Type 2 Diabetes in a Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Body mass index and risk of infections: a Mendelian randomization study of 101,447 individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Lone Larsen
  • Tine Jess
  • Asbjørn M Drewes
  • Anders Dige
  • Jan Fallingborg
  • Bent A Jacobsen
  • Bitten Aagaard
  • Jørgen Agnholt
Vis graf over relationer

OBJECTIVE: Loss of infliximab (IFX) effect is a clinical challenge in the management of patients with Crohn's disease (CD), but this can potentially be reduced with azathioprine (AZA) or with corticosteroids (CS). We aimed to study whether CS premedication with or without cotreatment with AZA could reduce antibody formation and affect the IFX elimination rate.

PATIENTS AND METHODS: A cross-sectional observational study was conducted at two centers with CD patients receiving maintenance IFX therapy for 12-18 months. In addition to IFX, patients received either CS premedication or not, with or without concominant AZA.

RESULTS: Fifty-seven patients were included in the study. Thirty-one patients received premedication with CSs, and 11 (35.5%) of these also received AZA, whereas this was the case for 22 of 26 (84.6%) patients in the non-CS group. No difference in IFX trough level (P=0.10) or halftime elimination (P=0.31) was observed with or without CS premedication. Concomitant AZA was associated with significantly longer mean half-life of IFX (P=0.04). Total IFX antibody concentrations were 15.8 and 12.9 with and without CS, respectively, in those not receiving AZA versus 4.3 and 6.1 AU/ml with and without CS, respectively, in those receiving AZA (P=0.004). Premedication with CS did not have any effect on the frequency of antibody formation (P=0.28).

CONCLUSION: In patients with CD and in maintenance IFX therapy, premedication with CS did not influence antibody formation, IFX trough levels or IFX halftime elimination, irrespective of concomitant AZA use. However, the use of AZA was associated with higher IFX trough levels and lower total IFX antibody concentrations.

OriginalsprogEngelsk
TidsskriftEuropean journal of gastroenterology & hepatology
Vol/bind31
Udgave nummer8
Sider (fra-til)964-967
Antal sider4
ISSN0954-691X
DOI
StatusUdgivet - 2019

ID: 57199410